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Abstract 
 
Context: Low IGF-I signaling activity prolongs lifespan in certain animal models, but the precise role 
of IGF-I in human survival remains controversial. The IGF-I kinase receptor activation assay (IGF-I 
KIRA) is a novel method for measuring IGF-I bioactivity in human serum. We speculated that 
determination of circulating IGF-I bioactivity is more informative than levels of immunoreactive IGF-
I. 
 
Objective: To study IGF-I bioactivity in relation to human survival.  
 
Design: Prospective observational study. 
 
Setting: A clinical research center at a university hospital. 
 
Study participants: 376 healthy elderly men (aged 73 to 94 years). 
 
Main outcome Measures: IGF-I bioactivity was determined by the IGF-I KIRA. Total and free IGF-I 
were determined by IGF-I immunoassays. Mortality was registered during follow-up (mean 82 
months). 
 
Results: During the follow-up period of 8.6 years 170 men (45%) died. Survival of subjects in the 
highest quartile of IGF-I bioactivity was significantly better than in the lowest quartile, both in the 
total study group (HR = 1.8, (95% CI: 1.2 − 2.8, p = 0.01) as well as in subgroups having a medical 
history of cardiovascular disease (HR = 2.4 (95% CI: 1.3 − 4.3, p = 0.003) or a high inflammatory risk 
profile (HR = 2.3 (95% CI: 1.2 − 4.5, p = 0.01). Significant relationships were not observed for total 
or free IGF-I. 
 
Conclusion: Our study suggests that a relatively high circulating IGF-I bioactivity in elderly men is 
associated with extended survival and with reduced cardiovascular risk. 
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Introduction 
 
Insulin-like growth factor I (IGF-I) has 
important anabolic and mitogenic effects, and 
is involved in mechanisms of function, 
maintenance, and repair of many tissues (1). 
Involvement of IGF-I in the process of aging 
has been studied extensively in the last two 
decades. Studies in invertebrates have 
suggested that disruption of signalling 
pathways similar to the IGF-I pathway extends 
lifespan (2-5). Growth hormone/IGF-I 
deficient mice and rats have increased 
longevity compared to controls (3, 6, 7). Also, 
decreased IGF-I receptor (IGF-IR) signalling 
activity in female heterozygous knockout mice 
was shown to retard the process of aging (8). 
However, the precise role played by IGF-I in 
human survival remains controversial (9). 
IGF-I is part of a complex system consisting of 
two growth factors (IGF-I and IGF-II), at least 
six high-affinity IGF binding proteins (IGFBP-
1 to -6) and several IGFBP proteases (1, 10). It 
is believed that only 0.5-1% of total IGF-I 
levels circulates in a free form, whereas about 
99% of circulating IGF-I is bound by IGFBPs. 
Only free IGF-I is considered to interact with 
the IGF-IR (11). 
Most of what is known about regulation of 
IGF-I in the circulation is based on 
measurements using specific IGF-I 
immunoassays. Since IGFBPs interfere with 
the accurate determination of IGF-I by 
immunoassay, various techniques have been 
developed to remove IGFBPs from samples or 
neutralize their influence on IGF-I 
immunoreactivity (11, 12). However, it is 
important to note that IGFBPs are important 
modulators of IGF-I bioactivity (1). IGFBPs 
are able to alter IGF-I bioactivity without 
changing the extractable concentrations of 
total IGF-I (11).  
Recently, a highly sensitive and IGF-I specific 
kinase receptor activation assay (IGF-I KIRA) 
was developed to determine IGF bioactivity in 
human serum (13, 14). This bioassay 
determines the ability of circulating IGF-I to 
activate the IGF-IR by quantification of 
intracellular receptor auto-phosphorylation 
upon IGF-I binding. Unlike an immunoassay, 
the IGF-I KIRA does not disregard modifying 
effects of IGFBPs and IGFBP proteases on the 
interaction between IGF-I and the IGF-IR (15, 
16). Therefore, the IGF-I KIRA method is a 
new tool that could help broaden our 
understanding of the IGF-I system in humans, 
in both normal and pathological conditions. 
The objective of the present study was to 
investigate whether IGF-I bioactivity was 
related to survival in a cohort of healthy 
elderly men. In addition, we studied the 
relationship between IGF-I bioactivity and 
cardiovascular disease (CVD) in this cohort. 
 
 
Research Design and Methods 
 
Study Population 
The design of the Zoetermeer study, a 
prospective cohort study conducted in 
clinically healthy independently living 
Caucasian elderly men, has been reported 
previously (17). Individuals were drawn from 
the municipal register of Zoetermeer, the 
Netherlands. Inclusion criteria were male sex, 
age ≥ 70 years and a sufficient physical and 
mental status to visit the study center 
independently. The Medical Ethics Committee 
of the Erasmus MC approved the study. Out of 
1567 invited men, 403 participated and gave 
written informed consent. At baseline, medical 
histories were obtained from all participants, 
and serum samples were collected from 376 
individuals. General practitioners were 
contacted about the status of participants in 
subsequent years. Cause of death was derived 
from death certificates and could only be 
verified in a limited number of subjects. The 
maximum follow-up time was 8.6 years. 
Information on nonfatal events was not 
registered.  
 
Anthropometric measurements 
Height and weight were measured. Systolic 
(SBP) and diastolic (DBP) blood pressures 
were measured in duplicate. Hypertension was 
defined as SBP > 160 mmHg and/or DBP > 90 
mmHg or antihypertensive treatment. Lean 
body mass and fat mass were measured using 
dual-energy X-ray absorptiometry (Lunar 
Corp., Madison, Wisconsin) (18).  
 
Assays 
At baseline, a venous blood sample was 
collected after an overnight fast. Serum and 
plasma aliquots were stored immediately after 
processing at -40°C. Total IGF-I levels were 
measured by radioimmunoassay (RIA) 
(Mediagnost GmbH, Tübingen, Germany) 
(19). Intra-assay and inter-assay coefficients of 
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variation (CVs) were 1.6% and 6.4%, 
respectively. Free IGF-I levels were measured 
by a non-competitive, two-site 
immunoradiometric assay (Beckman Coulter, 
Inc., Webster, Texas). Intra-assay and inter-
assay CVs were 10.3% and 10.7% 
respectively. IGFBP-1 and IGFBP-3 levels 
were determined by specific RIA as previously 
described (19). For IGFBP-1 and IGFBP-3, 
intra-assay CVs were 3.4% and 1.9%, 
respectively, and inter-assay CVs were 8.1% 
and 9.2%, respectively. Insulin was measured 
by a commercially available RIA (Medgenix 
Diagnostics, Brussels, Belgium). Intra-assay 
and inter-assay CVs were 8.0% and 13.7%, 
respectively. Immunoassays were performed 
soon after sample collection (in 1998) to 
reduce the possibility of analyte degradation.  
Insulin sensitivity was calculated according to 
the Homeostasis Model Assessment (HOMA) 
model 2 (HOMA Calculator v2.2, Oxford 
Centre for Diabetes, Endocrinology and 
Metabolism). Total and high-density 
lipoprotein (HDL) cholesterol and 
triglycerides were measured using a 
commercially available kit (17). Low-density 
lipoprotein (LDL) cholesterol levels were 
calculated. C-reactive protein levels (CRP) 
were determined with a highly sensitive 
method (hs-CRP) using a latex-enhanced 
immunoephelometric assay on a BN II 
analyzer (Dade Behring, Liederbach, 
Germany).  
 
IGF-I Kinase receptor activation assay (IGF-
I KIRA) 
IGF-I bioactivity was measured using an in-
house IGF-I KIRA as previously described 
(13). Human embryonic renal cells (293 
EBNA, Invitrogen, Germany) stably 
transfected with copy DNA of the human IGF-
IR gene were used as read-out after 
stimulation with either recombinant IGF-I 
standards (Austral Biologicals, San Ramon, 
CA) or 1/10 diluted serum samples. IGF-I 
standards, two control samples, and serum 
samples from study participants were 
measured in duplicate on each culture plate. 
Intra-assay and inter-assay CVs were 6.0% 
and 10.9%, respectively. IGF-I KIRA 
measurements were performed in 2005. There 
are no data on the effects of long-term storage 
on sample IGF-I activity in the KIRA assay. 
However, since all samples were analyzed 
following an equal period of storage, any 
variable effect of storage time is likely 
removed.  
 
Statistical Analysis 
Data were analyzed using SPSS for Windows, 
release 12.0 (Chicago, Illinois). Only data 
from the 376 participants for whom serum 
samples were available were included in the 
analyses. The Shapiro-Wilk test was used to 
test normality of variables (data were 
considered to be normally distributed when p 
> 0.05). For data that did not meet the criteria 
for normality, logarithmic transformations 
were applied. Baseline characteristics are 
presented as means ± SD, medians with 25th 
and 75th percentiles (P25 − P75), or numbers. 
Correlation coefficients (rs) between IGF-I 
parameters were calculated using non-
parametric tests (Spearman’s correlation 
coefficient). Univariate general linear models 
were used to calculate adjusted differences in 
means of variables between groups (F-tests 
were used to evaluate significance). Linear 
regression was used to calculate the relation 
between IGF-I bioactivity and age. A multiple 
linear regression model was used to test 
equality of slopes (IGF-I bioactivity = β0 + β1 
× age + β2 × Z + β3 × age × Z + E), where Z = 
1 for non-survivors; Z = 0 for survivors and E 
denoting independent, identically normally 
distributed error terms. IGF-I bioactivity and 
free IGF-I were calculated as percentage of 
total IGF-I according to the formula: X 
(pmol/L) / total IGF-I (pmol/L) x 100% (X = 
IGF-I bioactivity or free IGF-I level, 
respectively). 
Cox proportional hazard models were used to 
analyse survival (Wald tests were used to 
evaluate significance of variables in the hazard 
model). The time-to-event variable was 
specified as time from baseline examination to 
death denoted in months. Individuals who did 
not have an event during the time that the 
subject was part of the study (N = 206) were 
censored. Continuous IGF-I risk factors were 
grouped (group 1: ≤ 25th, group 2-3: 25th − 75th 
and group 4: ≥ 75th percentiles) and used as 
categorical covariates in survival analyses. For 
all IGF-I parameters risk was calculated 
relative to the highest quartile. Within the final 
model, age, BMI, smoking, SBP, diabetes, 
LDL and HDL were considered possible 
confounders and were used as baseline time-
constant covariates. Both crude and adjusted 
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hazard ratios (HR) were estimated. 
Assumptions of proportionality of hazards 
were verified by graphical inspection. To 
control for confounding by cardiovascular 
disease (CVD) or inflammatory risk status, 
crude data were stratified and survival analysis 
was repeated as described previously. To 
correct for CVD, crude data were stratified 
into two groups split by the presence (N = 
133) or absence (N = 242) of prevalent CVD. 
Presence of CVD was defined as having a 
medical history of myocardial infarction or 
cerebrovascular disease, and/or being treated 
or having symptoms of angina pectoris, 
congestive heart failure or claudicatio 
intermittens (17). To correct for inflammatory 
risk status continuous baseline hs-CRP levels 
were split at 3 mg/L, resulting in subjects with 
a low to medium inflammatory risk profile 
(IRP) (hs-CRP ≤ 3 mg/L, N = 238) and 
subjects with a high IRP (hs-CRP > 3 mg/L, N 
= 138) (20, 21). Survival analysis using IGF-I 
risk groups as categorical covariates was 
performed in IRP and CVD strata as described 
previously. 
In general: cause of death was based on death 
certificates that could not be verified in the 
majority of subjects. Therefore, cause of death 
was not controlled for in all Cox proportional 
hazard models. Trends across IGF-I risk 
groups were based on models with linear 
effect of the risk factors (Armitage trend test). 
Two-sided P-values are reported and P-values 
< 0.05 were considered statistically significant. 
 
 
Results 
 
Baseline characteristics of participants, 
categorized by survivors (N = 206, (55%)) and 
non-survivors (N = 170, (45%)), are shown in 
Table 1. Mean age at baseline was 77.7 ± 3.5 
(mean ± SD) years (range, 73 to 94). Mean 
time to death was 81.9 months (range, 3 to 
103).  
Baseline levels of IGF system parameters are 
shown in Table 2. Overall, IGF-I bioactivity 
and free IGF-I levels accounted for 2.6% 
(range, 0.2−5.9) and 0.6% (range, 0.2 − 2.9) of 
circulating total IGF-I levels, respectively (p < 
0.001). These fractions were not significantly 
correlated with each other (rs = 0.04, p = 0.48). 
At baseline, only mean IGFBP-1 levels 
differed significantly between survivors and 
non-survivors (Table 2). In addition, the mean 
calculated bioactive IGF-I fraction was 
significantly higher in survivors compared to 
non-survivors (mean ± SEM: 2.7 ± 0.06% vs. 
2.4 ± 0.07%, adjusted for age p = 0.04), 
whereas the calculated mean free IGF-I 
fraction did not differ between these groups (p 
= 0.62). Also the mean total IGF-I / IGFBP3 
ratio did not differ between survivors and non-
survivors (adjusted for age p = 0.21). 
IGF-I bioactivity was significantly correlated 
with all studied parameters of the IGF system 
(Table 3) and to the total IGF-I / IGFBP-3 
ratio (rs = 0.26, p < 0.001). Furthermore, mean 
baseline IGF-I bioactivity was negatively 
related to age (slope (β) = -4.5 pmol/L/year, p 
= 0.01, data not shown).  However, the rate of 
decline in IGF-I bioactivity with age did not 
differ between survivors (β = -3.5 
pmol/L/year) and non-survivors (β = -4.1 
pmol/L/year, p = 0.77). We found no 
significant correlations between IGF-I 
bioactivity and BMI, WHR, lean mass, fat 
mass, fasting glucose or insulin (data not 
shown). 
Survival analyses for risk factor groups (1, 2-3 
and 4) of total IGF-I, free IGF-I and IGF-I 
bioactivity were performed. Hazard ratios 
(HR) for mortality rate between groups are 
shown in Table 4.  
Cox proportional hazard plots are shown in 
Figures 1A, B and C, respectively. A 
significant relationship was found between 
groups of IGF-I bioactivity and mortality 
(Table 4, Figure 1C). Subjects within the 
highest quartile of IGF-I bioactivity (group 4) 
had a lower mortality rate than subjects in 
groups with lower IGF-I bioactivity (groups 1 
and 2-3). This remained significant after 
adjustment for age, BMI, smoking, SBP, 
diabetes, LDL and HDL (Table 4). For total 
IGF-I and free IGF-I no significant 
relationships were found (Table 4, Figure 1A 
and 1B respectively). In addition, when 
survival was analysed using quartiles of total 
IGF-I / IGFBP3 ratios no significant 
relationship was found (adjusted for age p for 
trend = 0.41, data not shown). 
The data were then stratified into subgroups 
with either positive (N = 133) or negative 
medical history of CVD (N = 242). Mean 
baseline levels of IGF-I bioactivity and all 
other measured parameters of the IGF system 
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did not differ between these two CVD groups 
(data not shown).  
There was a significant relationship between 
groups of IGF-I bioactivity and mortality in 
subjects with prevalent CVD (Table 4, Figure 
2A).  
Subjects in the lowest quartile (group 1) of 
IGF-I bioactivity had a significantly higher 
mortality rate than subjects in the highest 
quartile (group 4) (unadjusted p for trend = 
0.003; adjusted p for trend = 0.004).  
For group 1 vs. 2-3 the HR for mortality rate 
was significant (unadjusted HR = 2.3 (CI 95%: 
1.4 − 3.8, p = 0.001); adjusted HR = 2.1 (CI 
95%: 1.3 − 3.6, p = 0.005).  
IGF-I bioactivity was significantly inversely 
related to hs-CRP levels (rs = -0.17, p < 0.001, 
adjusted for age and BMI). Of all other 
measured parameters of the IGF-I system, only 
IGFBP-1 levels were significantly positively 
correlated with hs-CRP levels (r = 0.15, p = 
0.04, adjusted for age and BMI).   
Using hs-CRP as a marker of inflammation 
and mortality risk, we stratified data into a 
subgroup with a low to medium (N = 238) and 
with a high (N = 138) inflammatory risk 
profile (IRP). At baseline, mean IGF-I 
bioactivity was lower in subjects with a high 
IRP, than in subjects with a low to medium 
IRP (mean ± SEM: 312 ± 11.6 vs. 344 ± 7.8 
pmol/L, p = 0.01, adjusted for age and BMI). 
Means of other parameters of the IGF-I system 
did not differ between IRP subgroups.  
The relationship between IGF-I bioactivity 
groups and mortality was significant, but only 
in subjects with a high IRP (Table 4, Figure 
2B). Subjects in the highest quartile (group 4) 
had significantly better survival than subjects 
in the lowest quartile (group 1) (p = 0.01). 
This relationship remained significant after 
adjustment for age, BMI, smoking, SBP, 
diabetes, LDL and HDL (p = 0.03). Exclusion 
of the first year of follow-up, did not affect 
this relationship as the difference in mortality 
rate remained significant for group 1 vs. 4 
(unadjusted HR = 2.0, 95% CI: 1.1 − 4.3, p = 
0.02; adjusted HR = 2.0, 95% CI: 1.0−4.0, p < 
0.05). For group 1 vs. 2-3 the HR for mortality 
rate was not significant (unadjusted HR = 1.2 
(CI 95%: 0.8 − 2.0, p = 0.38; adjusted HR = 
1.0 (CI 95%: 0.6 − 1.8, p = 0.88).  
Lastly, IRP and CVD data were combined.  At 
baseline, mean IGFBP-1 levels were 
significantly higher in subjects with a positive 
medical history of CVD and/or a high IRP (N 
= 211) compared to individuals without 
prevalent CVD and a low/medium IRP, p = 
0.004, data not shown). 
A significant trend for mortality rates was 
found across IGF-I bioactivity groups in 
subjects with a high IRP and/or a positive 
medical history of CVD (unadjusted p for 
trend = 0.003; adjusted p for trend = 0.005; 
Figure 2C). Mortality rate was highest in 
group 1, the quartile with the lowest IGF-I 
bioactivity (for estimated HRs see legends of 
Figure 2C).  
Neither total nor free IGF-I showed any 
significant relationships with mortality rate in 
CVD and IRP subgroups (Table 4). 
 
 
Discussion 
 
This 8-year prospective study in elderly men 
showed that higher circulating IGF-I 
bioactivity is associated with better overall 
survival. Individuals in the lowest quartile of 
IGF-I bioactivity had a 1.8-fold increased 
mortality risk compared with individuals in the 
highest quartile. Interestingly, for total and 
free IGF-I measurements as well as for the 
total IGF-I / IGFBP-3 ratios we could not find 
such relationships. 
Although men with lower IGF-I bioactivity 
might have died earlier or might have been 
excluded from the study because their physical 
condition (illness, frailty or other causes) 
prevented a visit to the research center (22), 
the strength of our study is its prospective 
design, which is likely to reduce this form of 
selection bias.   
The IGF-I KIRA was used to measure IGF-I 
bioactivity (13, 14), which was significantly 
associated with other IGF-I system parameters 
measured by immunoassay. However, none of 
these associations had correlation coefficients 
greater than 0.5. This suggests that, in 
comparison with immunoassays, the KIRA 
produces different information about 
circulating IGF-I.  
In most IGF-I immunoassays, various 
techniques are used to remove IGFBPs (15). 
However, one of the major functions of 
IGFBPs is to modulate IGF-I bioavailability. 
IGFBP-1 is thought to be an important direct 
modulator of IGF-I bioactivity (10). In our 
study IGF bioactivity correlated better with 
circulating IGFBP-1 levels than with either 
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total or free IGF-I levels, suggesting that 
IGFBP-1 indeed influences IGF-I bioactivity. 
Of interest is the observed discrepancy 
between IGF-I bioactivity and free IGF-I in 
our study. Both parameters are believed to be 
informative about the fraction of circulating 
total IGF-I that interacts with the IGF-IR. 
Mean IGF-I bioactivity was significantly 
greater than mean free IGF-I level and 
correlation between these parameters was 
poor. An explanation could be that the IGF-I 
KIRA is more sensitive than free IGF-I levels 
in estimating the concentration of circulating 
IGF-I that interacts with the IGF-IR, since the 
KIRA is probably better at detecting the 
modulatory effects of IGFBPs and IGFBP 
proteases. In addition, as the IGF-I KIRA 
measures the overall ability of serum to 
activate the IGF-IR in vitro, our data do not 
allow us to discriminate between the relative 
contributions of IGF-I and IGF-II to the IGF-I 
KIRA signal. Therefore, IGF-II mediated 
effects could also have contributed to the 
discrepancy between the IGF-I KIRA and free 
IGF-I levels. From previous experiments it is 
known that IGF-II has a cross-reactivity of 
about 12% to the IGF-I receptor (13). 
However, as has been suggested previously, 
from a biological point of view it is not 
important whether IGF-IR activation is caused 
mostly by IGF-I or IGF-II (23). 
In this study a relatively high circulating IGF-I 
bioactivity was associated with a lower 
mortality risk. This is in contrast to results 
reported in animal studies, where low 
circulating IGF-I levels were associated with 
increased survival. An explanation could be 
that in these animal studies effects of IGF-I on 
the rate of aging were studied during lifelong 
exposure, whereas our study only provides 
insight into IGF-I activity towards the end of 
life. In addition, insulin and IGF-I have very 
different functions and signalling pathways in 
mammals compared with their homologs in 
lower species (e.g. C. elegans and 
Drosophila). Furthermore, lifespan in humans 
is measured in decades as opposed to months 
or days in rodents, flies and nematodes (24). 
Another explanation could be that catabolism 
and/or a systemic inflammatory response as a 
consequence of subclinical (undiagnosed) 
diseases may have induced resistance to IGF-I 
production. It could be that in our study low 
IGF bioactivity may not be a cause but rather 
an effect, serving as a reporter for disease or 
catabolism.  
Humans have the potential to live for over 100 
years and the precise interactions of all factors 
that influence aging is complex.  In the 
Western world cardiovascular disease (CVD) 
and cancer are the most important 
determinants of human survival. Although 
cancer is also a common cause of death in 
animal models used to study longevity, CVD 
is not and is more specific to humans. When 
we stratified for the presence or absence of 
CVD, we found that low IGF-I bioactivity was 
an important independent risk factor for 
mortality rate in individuals with CVD.  
Interestingly, comparative results were found 
when data were stratified according to IRP 
(based on CRP levels), and the observed trend 
became even stronger when both groups were 
combined.   
Of note, CRP is a non-specific marker of 
systemic inflammatory responses and has 
emerged as the most powerful predictor of 
mortality due to CVD events among eleven 
other biomarkers (21). In our study CRP levels 
were significantly inversely related to IGF-I 
bioactivity and positively to IGFBP-1. 
Although a decline in IGF-I bioactivity, as 
previously discussed, could be a component of 
the hormonal alterations that occur in any 
illness or catabolic state (37), the difference in 
mortality rate between the highest and the 
lowest quartile of IGF-I bioactivity in our 
study remained significant when all mortalities 
in the first year of follow-up were excluded 
from the analyses. Thus, undiagnosed illness 
or catabolic states at baseline probably did not 
cause the relationship between IGF-I 
bioactivity and survival.   
Interestingly, there are different clinical 
models that support the negative regulation of 
CRP and other inflammatory markers by 
GH/IGF-I administration (25, 26)  For 
example, Sesmilo et al. found low levels of 
CRP in patients with active acromegaly, which 
rose when IGF-I levels normalized after 
administration of a GH receptor antagonist 
(27). Verma et al. found that CRP negatively 
influences proliferation, differentiation and 
survival of isolated endothelial progenitor cells 
in vitro and their ability to produce nitric oxide 
(NO), whereas for IGF-I opposite effects have 
been reported (28, 29). Altogether these 
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findings point to the possibility of a 
relationship between IGF-I bioactivity, CRP 
and CVD.  However, it remains to be seen 
whether reduced IGF-I bioactivity is an 
endocrine contributor to mortality risk or 
simply an epiphenomenon related to overall 
health/resistance to inflammation. 
In conclusion, this prospective study provides 
evidence that low circulating IGF-I bioactivity 
in elderly men is associated with increased 
mortality, especially in those individuals in 
which an age-related pro-inflammatory state 
exists, with its attendant higher risk of 
mortality from CVD. Remarkably, for total 
and free IGF-I measurements we could not 
find such relationships. Compared to IGF-I 
immunoassays the IGF-I KIRA may offer the 
unique possibility of measuring the net 
modulating effects of IGFBPs and IGFBP 
proteases on IGF-IR activation by bioactive 
IGF-I available in human serum. In this 
respect, our study suggests that determination 
of IGF-I bioactivity may help to clarify the 
controversies that exist about the precise role 
of IGF-I in human survival. 
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Figure legends 
 
 
Figure 1: Cox proportional hazard plots (%) for groups of (A) circulating total IGF-I levels, (B) 
circulating free IGF-I levels and (C) IGF-I bioactivity levels. P for trend only reached statistical 
significance in the IGF-I bioactivity groups. Groups of IGF-I bioactivity: Group 1 (    ): ≤ 25th 
percentile; Group 2-3 (     ): between 25th and 75th percentile; Group 4 (     ): ≥ 75th percentile. Trends 
across IGF-I bioactivity risk groups were based on Cox proportional hazard models with linear effect 
of the risk factor (Armitage trend test). Maximum time of follow-up was 103 months. 
 
 
Figure 2: Crude incidence rates (number of events (deaths) per 100 person-years) are shown for 
groups of circulating IGF-I bioactivity levels according to strata of (A) absence or presence of a 
medical history of CVD (CVD - vs. CVD +, respectively), (B) low/medium or high inflammatory risk 
profile (IRPlow/medium vs. IRPhigh, respectively) and (C) combined subgroups of CVD and IRP (CVD+ 
and/or IRPhigh vs. CVD- and IRPlow/medium). A significant linear trend (*) between groups of IGF-I 
bioactivity was only found in subjects (A) with prevalent CVD, (B)  a high IRP or (C) prevalent CVD 
and/or a high IRP. Figure 2C; for group 1 vs. 2-3 unadjusted HR = 1.5 (95% CI: 1.0 − 2.3, p < 0.05) 
for group 1 vs. 4: HR = 2.3 (95% CI: 1.3 − 3.8, p = 0.002); and for group 2 vs. 3: HR = 1.5 (95% CI: 
0.9 − 2.5, p = 0.11). HRs adjusted for age, BMI, smoking, SBP, diabetes, LDL and HDL were 1.4 
(95% CI: 0.9 − 2.4, p = 0.15); 2.2 (95% CI: 1.3 − 3.8, p = 0.004); and 1.6 (95% CI: 0.9 − 2.6, p = 
0.08), respectively.   
Maximum time of follow-up was 103 months. Trends across IGF-I bioactivity risk groups were based 
on Cox proportional hazard models with linear effect of the risk factor (Armitage trend test). Groups 
of IGF-I bioactivity: Group 1: IGF-I bioactivity ≤ 25th percentile; Group 2-3: IGF-I bioactivity 
between 25th and 75th percentile; Group 4: IGF-I bioactivity ≥ 75th percentile. CVD = cardiovascular 
disease, IRP = inflammatory risk profile. IRP subgroups were based on hs-CRP levels: IRPlow/medium = 
CRP ≤ 3 mg/L, IRPhigh = CRP > 3 mg/L.  
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Table 1. Baseline characteristics of survivors and non-survivors in the study cohort (N = 376) 
Variable           Survivors 
        (N = 206) 
  Non-Survivors 
       (N = 170) 
P-value 
 
 
Mean ± SD 
 
 
Age (year) 
 
77.1 
 
±  
 
3.0 
 
78.5 
 
±  
 
3.9 
 
< 
 
0.001 
BMI (kg/m2) 25.8 ±  2.9 25.2 ±  3.0 < 0.29 
Lean mass (kg) 52.3 ±  5.5 51.4 ±  5.4 < 0.21 § 
Fat mass (kg) 21.3 ±  5.7 21.0 ±  5.7   0.84 § 
SBP (mmHg) 157 ±  25 156 ±  24   0.85 # 
DBP (mmHg) 84 ±  11 83 ±  11  0.49 # 
Total cholesterol (mmol/L) 5.8 ±  1.0 5.7 ±  1.1   0.53 # 
Glucose (mmol/L) ≈ 5.5 ±  1.2 5.4 ±  1.0   0.82 # 
         
  
Median (P25 – P75) 
  
Insulin (IU/L)≈     8.0  (6.0 − 10.0)     8.3  (6.2 − 10.6)   0.27 # 
HOMA (%S) 96 (71 − 124) 94 (75 − 124)  0.73 # 
  
Number (%) 
 
 
Smoking 37 (18%) 33 (19%)  0.89 
Hypertension 114 (55%) 116 (68%)  0.01 # 
Myocardial Infarction 24 (12%) 39 (23%)  0.002 
Malignancy 18 (9%) 14 (8%)  0.91 
Diabetes mellitus     14 (6.8%) 17 (10%)  0.30 
All values are unadjusted. P values were adjusted for age. §, P values for lean mass and fat mass were 
additionally adjusted for height. #, §, P values for blood pressures, lipids, glucose, insulin, HbA1c and HOMA 
(%S), were additionally adjusted for body mass index. ≈, Diabetics were excluded in the analysis of means for 
glucose, insulin and HbA1c. BMI – body mass index, SBP = systolic blood pressure, DBP = diastolic blood 
pressure, P25 – P75 = range between the 25th and 75th percentile, Insulin sensitivity in percentage (%S) was 
calculated according to the Homeostasis Model Assessment (HOMA) model 2 (HOMA Calculator v2.2, Oxford 
Centre for Diabetes, Endocrinology and Metabolism). 
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Table 2. Means at baseline of parameters of the IGF-I system in the total study population, in 
survivors and in non-survivors after follow-up 
 
Variable   Unit All subjects  
(N = 376) 
Survivors  
(N = 206) 
Non-Survivors  
(N = 170) 
P–value* 
  Mean or geometric mean (CI 95%)  
IGF-I 
Bioactivity 
 
pmol/L 
 
333 
 
(320 − 346) 
 
344 
 
(328 − 361) 
 
317 
 
(296 − 337) 
 
0.09 
Total IGF-I nmol/L 13.3 (12.9 − 13.6) 13.3 (12.7 − 13.7) 13.2 (12.6 − 13.9) 0.72 
Free IGF-I pmol/L 76.2 (72.2 − 80.3) 77.0 (72.1 − 82.2) 75.4 (69.1 − 82.2) 0.58 
IGFBP-1 nmol/L 1.1 (1.1 − 1.2) 1.1 (1.0 − 1.1) 1.2 (1.1 − 1.3) 0.03 
IGFBP-3 nmol/L 90.5 (88.0 − 93.0) 93.4 (90.1 − 96.9) 86.7 (83.1 − 90.2) 0.20 
For Free IGF-I and IGFBP-1 geometric means are shown and CI 95% intervals were calculated by forward-
backward log-transformation. *, Age adjusted P-values were calculated between survivors vs. non-survivors. 
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Table 3. Correlation coefficients between parameters of the IGF-I system in the study population (N 
= 376) 
 
 
IGF-I bioactivity Total IGF-I Free IGF-I IGFBP-1 
Total IGF-I - 0.49** 
   
Free IGF-I - 0.19** - 0.37** 
  
IGFBP-1 - 0.25** - 0.15** - 0.10* 
 
IGFBP-3 - 0.34** - 0.52** - 0.17** - 0.23** 
Correlations are presented as Spearman coefficients. *, P  < 0.05, **, P < 0.01. 
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Table 4. Estimated hazard ratios between groups of IGF-I bioactivity, total IGF-I and free IGF-I in all subjects and after stratification for CVD + and CVD- 
and IRPlow/med and IRPhigh, respectively, during a follow-up period of 8.6 years 
 
Group* All Subjects CVD - CVD + IRPlow/med IRPhigh 
  
HR CI 95% Pfor 
 trend 
HR CI 95% Pfor 
trend 
HR CI 95% Pfor 
trend 
HR CI 95% Pfor 
trend 
HR CI 95% Pfor 
trend 
A. Unadjusted 
 
               
1 1.8 1.2 − 2.8  1.6 0.9 − 2.9  2.4 1.3 − 4.3  1.4 0.8 − 2.5  2.3 1.2 − 4.5  IGF-I  
Bioactivity 2-3  1.2 0.8 − 1.8  1.4 0.8 − 2.5  1.1 0.6 − 1.9  1.0 0.6 − 1.6  1.9 1.0 − 3.6  
 4 Ref … 0.01 Ref … 0.12 Ref … 0.01 Ref … 0.32 Ref … 0.01 
                 
1 0.9 0.6 − 1.4  0.8 0.4 − 1.4  1.2 0.7 − 2.1  0.8 0.5 − 1.8  1.0 0.5 − 1.8  Total  
IGF-I 2-3 0.6 0.4 − 0.9  0.7 0.4 − 1.2  0.6 0.4 − 1.1  0.6 0.3 − 0.9  0.9 0.5 − 1.6  
 4 Ref … 0.36 Ref … 0.29 Ref … 0.92 Ref … 0.12 Ref … 0.25 
                 
1 1.1 0.8 − 1.7  1.2 0.7 − 2.1  1.2 0.7 − 2.2  0.8 0.5 − 1.3  1.8 1.0 − 3.4  Free  
IGF-I 2-3  0.7 0.5 − 1.1  0.8 0.5 − 1.3  0.8 0.5 − 1.3  0.7 0.4 − 0.9  1.1 0.6 − 2.1  
 
4 Ref … 0.93 Ref … 0.75 Ref … 0.76 Ref … 0.15 Ref … 0.25 
B. Adjusted 
 
               
1  1.6 1.0 − 2.5  1.3 0.7 − 2.5  2.5 1.4 − 4.8  1.3 0.7 − 2.3  2.1 1.1 − 4.1  IGF-I  
Bioactivity 2-3  1.4 0.8 − 1.8  1.4 0.8 − 2.5  1.2 0.7 − 2.1  1.0 0.6 − 1.7  2.0 1.0 − 3.8  
 4 Ref … 0.04 Ref … 0.31 Ref … 0.01 Ref … 0.47 Ref … 0.03 
                 
1 0.9 0.6 − 1.3  0.8 0.4 − 1.4  1.1 0.6 − 1.9  0.7 0.4 − 1.3  1.1 0.6 − 2.1  Total  
IGF-I 2-3  0.7 0.5 − 1.0  0.8 0.5 − 1.4  0.6 0.3 − 1.0  0.6 0.4 − 0.9  1.0 0.5 − 1.9  
 4 Ref … 0.25 Ref … 0.37 Ref … 0.77 Ref … 0.10 Ref … 0.87 
                 
1 1.0 0.7 − 1.6  1.3 0.7 − 2.3  1.1 0.6 − 2.0  0.9 0.5 − 1.6  1.7 0.9 − 3.4  Free  
IGF-I 2-3  0.7 0.5 − 1.1  0.9 0.5 − 1.5  0.7 0.4 − 1.2  0.6 0.4 − 1.0  1.0 0.6 − 1.9  
 
4 Ref … 0.81 Ref … 0.94 Ref … 0.98 Ref … 0.39 Ref … 0.15 
Individuals were grouped according to their baseline levels of three different IGF-I parameters (IGF-I bioactivity, Total IGF-I and Free IGF-I). Group 1: IGF-I ≤ 25th 
percentile, Group 2-3: IGF-I between 25th and 75th percentile, Group 4: IGF-I ≥ 75th percentile. *, In all models group 4 is the reference group (HR = 1.0). (A) Unadjusted 
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models, (B) models adjusted for age, BMI, smoking, SBP, diabetes, LDL and HDL. CVD- = absence of cardiovascular disease, CVD+ = presence of cardiovascular disease, 
IRPlow/med = low to medium inflammatory risk profile, IRPhigh = high inflammatory risk profile. 
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